
According to GlobalData’s study of companies’ annual reports and earnings call transcripts in 2022, despite the ongoing volatile market conditions…
The adaptability of these rapid testing devices will likely benefit them not only in COVID-19 tests but in the overall…
The typical age for when colorectal cancer screening begins is around 50, at which point patients undergo either routine colonoscopy…
Lilly will likely maintain or increase its market share in the basal insulin space as the average out-of-pocket cost for…
Currently, GSK, AstraZeneca, Roche, and Aurinia Pharmaceuticals are the key players in the lupus marketplace, and GlobalData anticipates all four…
Psilocybin is naturally derived from psilocybin mushrooms, predominantly the magic mushroom, Psilocybe cubensis, while psilocin is the pharmacologically active metabolite…
GlobalData observed around 5% growth in the robotic accessories market from 2021 to 2022, compared with 30% growth from 2020…
GlobalData analysis reveals that alongside the recent development of ICD RPM devices, subcutaneous ICDs have been aggressively gaining market share…
Despite numerous policy interventions to curb obesity’s prevalence, the condition continues to rise across the 7MM.
According to GlobalData, Waylivra (volanesorsen) is another apoCII inhibitor marketed by Ionis in the EU for patients with FCS with…
The agreement between Eli Lilly and Janssen was established to allow the two companies to share resources to accelerate the…
Zygel is anticipated to launch in the US in Q3 2025 and is forecast to generate US sales of $17.9…
According to GlobalData, the market for the UC is filled with several different treatment options, and the pipeline is relatively…
In Q3 2022 it earned $1.14 billion in net revenue but that is a 17% drop from the same period…
GlobalData claims that monitoring data can also be coupled with AI software to recognize worsening conditions.
According to GlobalData’s Pharma Intelligence Center,13 homegrown vaccines have been approved for use against COVID-19 in China.
According to the analyst consensus forecast on the GlobalData Pharma Intelligence Center, the drug is expected to reach $438 million…
Leqembi is the second anti-Aβ mAb approved by the FDA for the treatment of Alzheimer’s Disease, following the FDA’s controversial…
Rapid urbanisation and population growth across APAC will increase the number of patients requiring surgical intervention, GlobalData claims.
GlobalData also shows that the second highest contributing market in the 68M is the APAC region, generating 33.2% of global…
The LC-SCRUM-AP initiative will screen patients, who have advanced or recurrent non-small cell lung cancer.
Bayer has invested in a new production and supply facility in Beijing to support its CVD and diabetes medicines supply…
Loading…
Something went wrong. Please refresh the page and/or try again.